Drug Trial Radar · NCT04417621
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
134
Actual
Start
Oct 30, 2020
Primary completion
Feb 2, 2027
Study completion Feb 2, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma
Conditions
- Melanoma
Interventions
LXH254Drug
LXH254 will be supplied as tablet for oral use.
LTT462Drug
LTT462 will be supplied as hard gelatin capsule for oral use.
TrametinibDrug
Trametinib will be supplied as film-coated tablet for oral use
RibociclibDrug
Ribociclib will be supplied in tablets and hard gelatin capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: 35 months
Locations
36 sites in 12 countries. Site status is shown where the registry gives one.
The Angeles Clinic and Research Institute
Los Angeles, California
UCSF Medical Center
San Francisco, California
Florida Cancer Specialists
Fort Myers, Florida
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic Mayo Rochester
Rochester, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota
NYU Laura and Isaac Perlmutter Cancer Center
New York, New York
Memorial Sloan Kettering
New York, New York
University of Pittsburgh Med Center
Pittsburgh, Pennsylvania
Univ of TX MD Anderson Cancer Cntr
Houston, Texas
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
North Sydney, New South Wales, Australia
Novartis Investigative Site
Wooloongabba, Queensland, Australia
Novartis Investigative Site
Subiaco, Western Australia, Australia
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Wilrijk, Belgium
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Pierre-Bénite, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Tübingen, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Ramat Gan, Israel
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Maastricht, Limburg, Netherlands
Novartis Investigative Site
Oslo, Norway
Novartis Investigative Site
Lausanne, Switzerland
Novartis Investigative Site
Zurich, Switzerland
Novartis Investigative Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.